Candel Therapeutics Inc [CADL] stock is trading at $8.99, up 3.57%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CADL shares have gain 2.16% over the last week, with a monthly amount glided 96.72%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Candel Therapeutics Inc [NASDAQ: CADL] stock has seen the most recent analyst activity on December 02, 2022, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $11. Previously, BMO Capital Markets started tracking the stock with Outperform rating on November 19, 2021, and set its price target to $18. On August 23, 2021, UBS initiated with a Buy rating and assigned a price target of $9 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $22 on August 23, 2021. Credit Suisse initiated its recommendation with a Outperform and recommended $15 as its price target on August 23, 2021.
Candel Therapeutics Inc [CADL] stock has fluctuated between $1.16 and $14.60 over the past year. Candel Therapeutics Inc [NASDAQ: CADL] shares were valued at $8.99 at the most recent close of the market.
Analyzing the CADL fundamentals
Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at -20.02%, Pretax Profit Margin comes in at -29.39%, and Net Profit Margin reading is -29.39%. To continue investigating profitability, this company’s Return on Assets is posted at -2.43, Equity is 32.1 and Total Capital is -5.69. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.43 points at the first support level, and at 7.88 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.28, and for the 2nd resistance point, it is at 9.58.
Ratios To Look Out For
For context, Candel Therapeutics Inc’s Current Ratio is 1.18. In addition, the Quick Ratio stands at 1.18 and the Cash Ratio stands at 1.08.
Transactions by insiders
Recent insider trading involved Manning Paul B, Director, that happened on Dec 16 ’24 when 1.25 million shares were purchased. Chief Technology Officer, Tyagarajan Seshu completed a deal on Nov 29 ’24 to sell 20392.0 shares. Meanwhile, Chief Executive Officer Tak Paul Peter sold 48847.0 shares on Nov 29 ’24.
